Ruxolitinib Tablets/Ruxolitinib Price Difference between Domestic Imported Original Drugs and Generic Drugs

Ruxolitinib tablets/ruxolitinib (JAKAVI) is an oral drug targeting the JAK1/2 pathway. It was developed by Novartis of Switzerland and marketed under the trade name JAKAVI. The drug is marketed in China as the original drug in the form of "ruxolitinib phosphate tablets" and is included in the National Medical Insurance Category B catalog. It is suitable for the treatment of myeloproliferative diseases such as myelofibrosis and polycythemia vera. Common specifications in the domestic market include 14 tablets of 20mg and 60 tablets of 5mg. The price is about RMB 3,000. Depending on local medical insurance policies, the patient's out-of-pocket payment ratio will also fluctuate. Due to high research and development costs, the price of original drugs is generally high around the world. Especially before they are fully included in the medical insurance system, the economic pressure on patients cannot be underestimated.

As the demand for treatment increases, multiple generic versions of ruxolitinib have appeared on the international market. For example, generic versions of ruxolitinib launched by Bangladesh Yaopin International and Laos Lucius Pharmaceuticals have the same ingredients as the original drug, and also have the same oral dosage form and usage. Taking the Bangladeshi market as an example, the price of a box of generic drugs with a specification of 5mg*50 tablets is about more than 1,000 yuan, which is far lower than the retail price of the original drug. This significantly lowers the threshold for self-paying patients or people with limited medical insurance reimbursement. However, since most generic drugs are obtained through overseas channels, they may be affected by factors such as exchange rates, logistics, and policies. Prices are highly volatile, and there are certain purchase and use risks.

From the perspective of pharmacological effects, the original drug and the qualified generic drug are highly consistent in active ingredients, bioequivalence and clinical efficacy. If the generic drug passes strict quality audit, it can also meet the treatment needs. However, in the context of domestic policies that have not fully liberalized the use of overseas generic drugs, patients should be extremely cautious when choosing generic drugs. They must obtain them through formal channels and use them under the guidance of a doctor.

Reference materials:https://www.jakavi.com/